IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 14, 2024 07:55 ET
|
IO Biotech
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine,...
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:30 ET
|
IO Biotech
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
April 15, 2024 08:30 ET
|
IO Biotech
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
April 09, 2024 12:00 ET
|
IO Biotech
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
April 05, 2024 08:30 ET
|
IO Biotech
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 06, 2024 16:11 ET
|
IO Biotech
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
March 05, 2024 16:40 ET
|
IO Biotech
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
IO Biotech to Present at 44th Annual Cowen Health Care Conference
February 26, 2024 16:05 ET
|
IO Biotech
IO Biotech to Present at 44th Annual Cowen Health Care Conference
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
December 21, 2023 08:30 ET
|
IO Biotech
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
IO Biotech Announces 2023 Third Quarter Results
November 13, 2023 08:12 ET
|
IO Biotech
IO Biotech Announces 2023 Third Quarter Results